-
Benchmarked therapeutic areas with high clinical and market potential
-
Developed potential market scenarios based on client needs
CLIENT CHALLENGES
- One of the top 10 pharmaceutical majors wanted to determine market attractiveness and assess opportunities for its asset being developed for CLL, MCL and WM
- Key challenges were:
- Benchmark therapeutic areas being based on diverse parameters involving clinical, regulatory and market assessment
- Building a 360-degree view of the market by combining market sizing with adoption share
- Market attractiveness based on regulatory/NCCN approval, adoption, reimbursement and market access
- Understanding niche therapeutic areas
OUR APPROACH
- Competitive analysis:
- Identified key competitors within each indication and patient population
- Conducted a detailed comparison of the client’s asset and each asset in the pipeline
- Scored the client’s asset in terms of clinical attractiveness within each indication
- Market sizing:
- Adopted a bottom-up sizing approach – from disease prevalence to the diagnosed and drug-treated population in major markets (the US and EU5)
- Key differentiator analysis:
- Generated revenue estimations in each indication based on adoption share
- Factored in the differences for adoption share and launch timelines and estimated duration of therapies
IMPACT DELIVERED
- Advised on the attractiveness of the indications among CLL, MCL and WM
- Created market scenarios based on regulatory approvals, reimbursement and market access
- Built a dashboard to enable the client to customise results based on assumptions
Thank you for sharing your details
Your file will start downloading automatically
If it does not download within 1 minute,
Share this on
